Faldaprevir Plus Pegylated Interferon Alfa-2a/Ribavirin in HIV/HCV Co‑infection: STARTVerso4
Background: Faldaprevir (FDV) is a potent, once-daily HCV NS3/4A protease inhibitor being developed for the treatment of chronic HCV infection in monoinfected patients and patients co-infected with HIV. The objective of STARTVerso4 is to assess efficacy and safety of FDV + pegylated interferon alfa-2a/ ribavirin (PR), and evaluate response-guided treatment duration in HIV patients co-infected…